NAMS Stock Forecast & Price Target

NewAmsterdam Pharma Co is viewed favorably because obicetrapib has shown consistent, meaningful LDL reductions in multiple ph.I and ph.II studies, with a clean safety profile, QD dosing, and no food effect that could support broad adoption as an oral switch or add-on therapy. The 9,500-patient PREVAIL outcomes trial is described as more than 90% powered to show a 20% MACE reduction, while even 15% would be clinically meaningful, and a more detailed model implies roughly a 25% risk reduction is needed for MACE-3 to clear an 80% PoS threshold. The commercial case is also strong, with significant unmet need among patients who are dissatisfied with current therapy or statin intolerant, potential for $1.6B in U.S. sales and $3.1B worldwide, and upside from European approval anticipated in 4Q26.

NewAmsterdam Pharma Co is viewed negatively because its value depends almost entirely on obicetrapib, a late-stage CETP inhibitor whose category has already seen prior failures and whose ability to deliver meaningful MACE benefit remains unproven. The company also faces a tougher commercial backdrop from approved oral PCSK9 inhibitors, genericized competition, and the loss of Lp(a) differentiation, while its composition-of-matter patent expires in 2027, weakening long-term exclusivity. Although estimates still point to a 2028 launch and $2.4B peak revenues by 2035, the stock is exposed to binary clinical, regulatory, reimbursement, and financing risks as a small biotech with no revenues.